Advertisement

Topics

Latest "Spriafil Drug Insights 2017 Updated 30052017 Prices from" News Stories

10:57 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Spriafil Drug Insights 2017 Updated 30052017 Prices from" found in our extensive news archives from over 250 global news sources.

More Information about Spriafil Drug Insights 2017 Updated 30052017 Prices from on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Spriafil Drug Insights 2017 Updated 30052017 Prices from for you to read. Along with our medical data and news we also list Spriafil Drug Insights 2017 Updated 30052017 Prices from Clinical Trials, which are updated daily. BioPortfolio also has a large database of Spriafil Drug Insights 2017 Updated 30052017 Prices from Companies for you to search.

Showing "Spriafil Drug Insights 2017 Updated 30052017 Prices from" News Articles 1–25 of 37,000+

Tuesday 26th March 2019

Confirm BioSciences Secures Funding with HCAP Partners to Accelerate Global Expansion

New Investment to Fuel New Product Innovations and Strategic Growth SAN DIEGO (PRWEB) March 26, 2019 Confirm BioSciences, the San Diego, CA-based leader for high-quality diagnostic testing and health & wellness solutions for both the corporate community and individual consumers, today announced it has secured impact financing from HCAP Partners, a California-based private equity firm and reco...


Medrio Announces Multi-Year Enterprise Agreement with Deep Intelligent Pharma (DIP) for eSuite of Services

The collaboration will create additional value for pharma R&D clients globally including China, Japan, Australia, the United States, and EMEA. SAN FRANCISCO (PRWEB) March 26, 2019 Xing Li, The founder and CEO of Deep Intelligent Pharma (DIP), and Shinya Yamamoto, The Managing Director of Medrio, Inc., Asia-Pacific Region, announced a strategic alliance between DIP and Medrio at DIP’s Beijin...

Postpartum depression: new drug will be monitored at approved sites

The first drug approved by the US Food and Drug Administration for the treatment for postpartum depression will be administered only to short term inpatients at specially approved sites, as the FDA...


EU approves AZ' Forxiga for type I diabetes

The drug is the first oral medicine approved in Europe as an adjunct to insulin for adults with type I diabetes.

Tiziana submits IND for Foralumab oral formulation in NASH

Tiziana has submitted an Investigational New Drug application for an oral formulation of Foralumab.

McKesson ideaShare Unites Independent Pharmacy

Premier community pharmacy education and networking event hits Orlando in 2019 Registration is now open for McKesson ideaShare in Orlando from June 26–30, 2019. Pharmacists, pharmacy owners and pharmacy technicians have the chance to

Applications of nanotech may provide bioavailability

Nanotechnology may be able to increase bioavailability in low-solubility drugs and improve a drugâs chance of success, according to Ascendia CEO.

Vivior’s System Cleared for CE Mark – Market Introduction This Year in Europe

Vivior has cleared their system as a Class I medical device and is planning the market introduction later this year in Switzerland and the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005594/en/ The Visual Behavior

Catalent Biologics to Present on Tech Transfer, Biomanufacturing and Aseptic Processing at INTERPHEX

Catalent Pharma Solutions (Booth 1145), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that two of its manufacturing experts will present at the INTERPHEX Conference and Exhibition, taking place at the Javits Center, New York City, on April 2-4, 2019. SOMERSET, N.J. (PRWEB) March 26, 2019 C...

Chamberlain University Names Dr. Simendea Clark President of Chicago Campus

Chamberlain University announced today that Dr. Simendea Clark, DNP, RN has been appointed president of its Chicago campus, one of three Chicagoland campuses. Dr. Clark is responsible for the Chicago campus nursing program and operations, including overall academic excellence, student services, support and success. Since joining Chamberlain in 201...

Covetrus Announces Appointment of Matthew Leonard as Executive Vice President, President North America and Global Supply Chain Officer

Leonard Brings Significant Expertise in Technology, Procurement and Supply Chain Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that Matthew Leonard has been named Executive Vice President, President North America and Global Supply Chain Officer effective April 8, 2019. In his role, Leonard will ...

Shaolian Zhou, Ph.D., Joins Worldwide Clinical Trials as Senior Vice President and Lab Director for Bioanalytical Services

Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global CRO, announced today that Shaolian Zhou, Ph.D., has joined the company as senior vice president and lab director for Bioanalytical Services. Based at the company’s Austin, Texas, Bioanalytic Laboratory, Dr. Zhou is responsible for the overall operations of...

Collective Medical Appoints Jim Lacy as President and Chief Operating Officer

Lacy to apply his proven approach to strategy, policy and product to accelerate rapid growth toward connecting the healthcare system at scale Collective Medical, delivering the nation’s largest and most effective network for care collaboration, today announced the appointment of Jim Lacy as president and chief operating officer. This press rele...

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

– In Clinical Trials, Biktarvy Demonstrated High Efficacy, Few Interactions with Other Drugs and a High Barrier to Resistance Through 48 Weeks – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, ...

Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial

Food allergy-focused Aimmune Therapeutics has announced its peanut allergy drug AR101 met its primary endpoint in Phase III European clinical...Read More... The post Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial appeared first on Pharmaceutical Technology.

Lipella Pharmaceuticals Received FDA IND Approval for Phase-2a Oncology Supportive Care Drug Study

LP-10, which has received FDA Orphan Drug designation, has now obtained IND approval for Phase-2a, multi-center, double-blind, controlled, clinical trial for hemorrhagic cystitis. Lipella Pharmaceuticals Inc., a clinical stage biopharmaceutical company based in Pittsburgh, PA, anno

ReviveMed Receives Frost & Sullivan AI-Driven Next-Generation Metabolomics Technology Innovation Award

ReviveMed is proud to announce that they are the recipient of the North American AI-Driven Next-Generation Metabolomics Technology Innovation Award from Frost & Sullivan as part of that company's 2018 Best Practices Awards. Frost & Sullivan, which has been providing a wide range of business consulting and market research analysis for over 50 years,...

Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting

- Data demonstrate how an HDAC inhibitor increases the tumor expression of SSTR2 with synergy of efficacy - Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors,

Charles River Laboratories Highlights Commitment to Oncology Research at 2019 AACR Annual Meeting

Researchers will highlight work in BRCA-deficient and rare pediatric cancers Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and two oral presentations to highlight its enhanced o...

Vela Diagnostics Announces FDA Submission of its Next Generation Sequencing (NGS) HIV Genotyping and Drug Resistance Mutation (DRM) Assay

Vela announces FDA submission for the Sentosa® SQ HIV Genotyping Assay, a Next Generation Sequencing (NGS) genotyping and drug resistance mutation (DRM) detection in vitro diagnostic test intended for use as an aid in monitoring and treating HIV-1 infection Vela Dia

Aldeyra's eye drug meets main goal in late-stage study, shares surge

Aldeyra Therapeutics Inc said on Tuesday its drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

Arix Bioscience’s portfolio company Autolus announces positive safety data for AUTO3 ahead of inaugural R&D day

Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease negative complete responses

Novo Nordisk's Ozempic outclasses Januvia with new data in type 2 diabetes

Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue Ozempic (oral semaglutide), indicating that the drug achieved “superior reductions” in blood sugar, and body weight compared to MSD’s Januvia (sitagliptin 100 mg). The therapy was tested in in type 2 diabetes patients whose condition was inadequately controlled with metformin, with or w...

Drug rehabilitation charities spent millions on generics price concessions in 2018

Non-NHS organisations, including charities and local authorities, have had to pay £5.6m for drugs under the generics price concessions scheme in 2018, data analysts have found.

Aldeyra's experimental drug reproxalap hits main goal in Phase III allergic conjunctivitis study https://www.firstwordpharma.com/node/1631347  $ALDX

Aldeyra's experimental drug reproxalap hits main goal in Phase III allergic conjunctivitis study https://www.firstwordpharma.com/node/1631347  $ALDX


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks